ARMP vs NTLA
ARMP: Armata is a clinical-stage phage biotech using engineered bacteriophages as a targeted, microbiome-friendly alternative to antibiotics for drug-resistant bacterial infections. NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
Side-by-side fundamentals
| Metric | ARMP | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.24 | $11.13 | |
| Market cap as of 2026-07-23 | $194M | $1.6B | |
| PEG as of 2026-07-23 | -0.00 | n/a | |
| Net margin as of 2026-07-23 | -5432.8% | -597.0% | NTLA higher |
| Operating margin as of 2026-07-23 | -715.6% | -636.6% | NTLA higher |
| ROE as of 2026-07-23 | -120.0% | -57.3% | NTLA higher |
| ROA as of 2026-07-23 | -356.6% | -46.1% | NTLA higher |
| Debt / equity as of 2026-07-23 | 1.38 | 0.00 | NTLA lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.7% | +45.0% | NTLA higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.1% | |
| Beta as of 2026-07-23 | 1.36 | 1.78 | |
| 1-year return as of 2026-07-22 close | +123.0% | -17.5% | ARMP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.